The company designed its user-friendly CareSens Air CGM to simplify diabetes management. It plans to make the system available in the UK in February, according to a post on LinkedIn. The post reads:
“Our new continuous glucose monitor (CGM), CareSens Air, will now be available on the Drug Tariff from February this year. This diabetes solution could be a valuable addition to your diabetes care portfolio.”
According to the Spirit Health website, the 15-day wear device has readings delivered directly to the user’s smartphone every five minutes. Its easy-to-use app and price make it a convenient, cost-effective solution for reliable glucose monitoring, the company says.
The CareSens Air sensor is an all-in-one device with an applicator for simple attachment. The slim and light sensor has an ergonomic design for an easy wear. Spirit Health designed a painless insertion process in which the applicator instantly attaches the sensor to the skin for minimal discomfort.
CareSens Air’s mobile application, a comprehensive platform for diabetes management, offers real-time updates. Users can visualize their glucose trends and changes over time. With personalized alerts, users can set custom thresholds for low, high and rapidly changing glucose levels. The app has lifelog integration, allowing for the tracking of activities and situations that impact glucose levels for better management.
Through the app and web, carers and healthcare professionals can remotely monitor and manage patients as well. They can view detailed reports, track trends and connect with patients. Spirit Health says personalized insights allow carers to analyze metrics, statistical indicators and lifelog events. Real-time monitoring provides access to live glucose data and connection to users for shared insights.
